Published in JAMA on November 06, 1997
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health (1998) 9.58
Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med (2000) 6.72
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.85
A longitudinal study of drivers with Alzheimer disease. Neurology (2008) 3.17
The older adult driver with cognitive impairment: "It's a very frustrating life". JAMA (2010) 1.80
Practice constraints, behavioral problems, and dementia care: primary care physicians' perspectives. J Gen Intern Med (2007) 1.72
Predictors of driving cessation in mild-to-moderate dementia. CMAJ (2006) 1.68
Alzheimer disease. Dis Mon (2010) 1.64
A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging (2008) 1.61
Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol (2008) 1.49
The relationship between Helicobacter pylori infection and Alzheimer's disease in Japan. J Neurol (2011) 1.44
Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med (2011) 1.44
Driving and dementia: a review of the literature. J Geriatr Psychiatry Neurol (2004) 1.39
APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. Annu Rev Clin Psychol (2009) 1.37
The cost-effectiveness of a behavior intervention with caregivers of patients with Alzheimer's disease. J Am Geriatr Soc (2007) 1.34
Evidence of a role for lactadherin in Alzheimer's disease. Am J Pathol (2007) 1.28
Relationship between frailty and cognitive decline in older Mexican Americans. J Am Geriatr Soc (2008) 1.21
Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest (2003) 1.19
Care of older people: Mental health problems. BMJ (2001) 1.19
Predictors of mortality in patients with Alzheimer's disease living in nursing homes. J Neurol Neurosurg Psychiatry (1999) 1.13
Caregivers for people with dementia. What is the family physician's role? Can Fam Physician (2000) 1.13
Association of cystatin C with adverse outcomes. Curr Opin Nephrol Hypertens (2009) 1.11
Prevalence of potentially reversible dementias and actual reversibility in a memory clinic cohort. CMAJ (1998) 1.09
Quality of Life measures for dementia. Health Qual Life Outcomes (2003) 1.09
Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial (PLASA study). BMJ (2010) 1.08
Metabolites of cerebellar neurons and hippocampal neurons play opposite roles in pathogenesis of Alzheimer's disease. PLoS One (2009) 1.07
The apolipoprotein E gene, attention, and brain function. Neuropsychology (2002) 1.05
Spontaneous social behaviors discriminate behavioral dementias from psychiatric disorders and other dementias. J Clin Psychiatry (2008) 1.05
Economic considerations in the management of Alzheimer's disease. Clin Interv Aging (2006) 1.03
Effects of a multimedia project on users' knowledge about normal forgetting and serious memory loss. J Am Med Inform Assoc (2002) 1.01
Redesigning systems of care for older adults with Alzheimer's disease. Health Aff (Millwood) (2014) 0.97
Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol (2006) 0.95
Apolipoprotein epsilon4 allele status, depressive symptoms, and cognitive decline in middle-aged and elderly persons without dementia. Am J Geriatr Psychiatry (2003) 0.95
Altered medial temporal lobe responses during visuospatial encoding in healthy APOE*4 carriers. Neurobiol Aging (2007) 0.94
Current pharmacologic options for patients with Alzheimer's disease. Ann Gen Hosp Psychiatry (2003) 0.94
What we need to know about age related memory loss. BMJ (2002) 0.94
Transdermal donepezil on the treatment of Alzheimer's disease. Neuropsychiatr Dis Treat (2012) 0.93
Cognitive training and cognitive rehabilitation for persons with mild to moderate dementia of the Alzheimer's or vascular type: a review. Alzheimers Res Ther (2013) 0.93
Integrating care for older adults with cognitive impairment. Curr Alzheimer Res (2009) 0.92
Detection of visuoperceptual deficits in preclinical and mild Alzheimer's disease. J Clin Exp Neuropsychol (2009) 0.91
Cost evaluation of a coordinated care management intervention for dementia. Am J Manag Care (2009) 0.90
Caregiver- and patient-directed interventions for dementia: an evidence-based analysis. Ont Health Technol Assess Ser (2008) 0.90
Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and in dementia: a review. J Aging Res (2012) 0.89
How does dementia affect driving in older patients? Aging health (2010) 0.88
"Thinking about it for somebody else": Alzheimer's disease research and proxy decision makers' translation of ethical principles into practice. Am J Geriatr Psychiatry (2013) 0.87
Seizures in an Alzheimer's disease patient as a complication of colonoscopy premedication with meperidine. Dig Dis Sci (2007) 0.87
Diagnosis of suspected Alzheimer's disease is improved by automated analysis of regional cerebral blood flow. Eur J Nucl Med Mol Imaging (2004) 0.86
Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease. Mol Neurodegener (2010) 0.86
Alzheimer's disease. Dialogues Clin Neurosci (2000) 0.86
Impact of gene patents and licensing practices on access to genetic testing for Alzheimer disease. Genet Med (2010) 0.86
Memantine: efficacy and safety in mild-to-severe Alzheimer's disease. Neuropsychiatr Dis Treat (2007) 0.84
Neuropsychological screening tests in African Americans. J Natl Med Assoc (2001) 0.84
Chemical composition, antioxidant and anticholinesterase potentials of essential oil of Rumex hastatus D. Don collected from the North West of Pakistan. BMC Complement Altern Med (2016) 0.84
Recognition and Management of Behavioral Disturbances in Dementia. Prim Care Companion J Clin Psychiatry (2001) 0.84
Caspases: therapeutic targets in neurologic disease. Neurotherapeutics (2015) 0.83
Genetic counseling throughout the life cycle. J Clin Invest (2003) 0.83
Invited commentary: lipoproteins and dementia - is it the apolipoprotein A-I? Am J Epidemiol (2007) 0.83
Cognitive assessment of older primary care patients with and without memory complaints. J Gen Intern Med (2007) 0.82
Positron emission tomography scanning for the early diagnosis of dementia. West J Med (2000) 0.82
The role of adenosine in Alzheimer's disease. Curr Neuropharmacol (2009) 0.81
Neuroprotection and neurodegeneration in Alzheimer's disease: role of cardiovascular disease risk factors, implications for dementia rates, and prevention with aerobic exercise in african americans. Int J Alzheimers Dis (2012) 0.81
Psychotic symptoms in the elderly. Prim Care Companion J Clin Psychiatry (2005) 0.81
A quick test of cognitive speed (AQT): usefulness in dementia evaluations in primary care. Scand J Prim Health Care (2013) 0.80
Risk of ischemic stroke associated with the use of antipsychotic drugs in elderly patients: a retrospective cohort study in Korea. PLoS One (2015) 0.80
Effectiveness of balance training exercise in people with mild to moderate severity Alzheimer's disease: protocol for a randomised trial. BMC Geriatr (2009) 0.79
Asking family about memory loss. Is it helpful? J Gen Intern Med (2005) 0.79
Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study. J Neurol (2005) 0.78
Potential drug-drug interactions in Alzheimer patients with behavioral symptoms. Clin Interv Aging (2015) 0.77
Behavioral disturbances in dementia. Dialogues Clin Neurosci (2003) 0.77
Longitudinal follow-up of late-onset Alzheimer disease families. Am J Med Genet B Neuropsychiatr Genet (2008) 0.77
Early diagnosis of Alzheimer's disease: update on combining genetic and brain-imaging measures. Dialogues Clin Neurosci (2000) 0.76
Central administration of angiotensin IV rapidly enhances novel object recognition among mice. Neuropharmacology (2013) 0.76
Health-related quality of life in the Cambridge City over-75s Cohort (CC75C): development of a dementia-specific scale and descriptive analyses. BMC Geriatr (2014) 0.76
National patterns of dementia treatment among elderly ambulatory patients. J Natl Med Assoc (2006) 0.76
Alzheimer's Disease. Curr Treat Options Neurol (2000) 0.76
Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer's disease. Am J Neurodegener Dis (2014) 0.75
Case of the month: rivastigmine (Exelon) toxicity with evidence of respiratory depression. Emerg Med J (2006) 0.75
Consensus Statement on Alzheimer disease. JAMA (1998) 0.75
Positron emission tomography for the early diagnosis of dementia. West J Med (2000) 0.75
End-of Life Issues in the Context of Alzheimer's Disease. Alzheimers Care Q (2003) 0.75
Early Dementia Screening. Diagnostics (Basel) (2016) 0.75
Direct Care Worker Training to Respond to the Behavior of Individuals With Dementia: The CARES® Dementia-Related Behavior(™) Online Program. Gerontol Geriatr Med (2016) 0.75
Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers. Drug Des Devel Ther (2015) 0.75
Practical Principles for the Management of Alzheimer's Disease. Prim Care Companion J Clin Psychiatry (2002) 0.75
Consensus Statement on Alzheimer disease. JAMA (1998) 0.75
Consensus Statement on Alzheimer disease. JAMA (1998) 0.75
Improving dementia diagnosis and management in primary care: a cohort study of the impact of a training and support program on physician competency, practice patterns, and community linkages. BMC Geriatr (2013) 0.75
Caring for relatives with agitation at home: a qualitative study of positive coping strategies. BJPsych Open (2017) 0.75
Long-term care eligibility criteria for people with Alzheimer's disease. Health Care Financ Rev (1999) 0.75
Spectrum of neurocognitive dysfunction in Indian population on FDG PET/CT imaging. Indian J Nucl Med (2011) 0.75
Patient-rated versus proxy-rated cognitive and functional measures in older adults. Patient Relat Outcome Meas (2017) 0.75
Long-term safety and tolerability of rivastigmine in patients with Alzheimer's disease switched from donepezil: an open-label extension study. Prim Care Companion J Clin Psychiatry (2008) 0.75
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Diagnosis of Alzheimer's disease. Arch Neurol (1985) 12.77
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry (1982) 10.83
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.68
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med (1997) 7.56
Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.51
Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci (1996) 7.19
Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med (2000) 6.72
Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci (2000) 6.54
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med (1992) 5.93
Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol (1998) 5.93
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA (2001) 5.13
Inhibition of Trypanosoma brucei gene expression by RNA interference using an integratable vector with opposing T7 promoters. J Biol Chem (2000) 4.96
Cancer linked to Alzheimer disease but not vascular dementia. Neurology (2009) 4.83
A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. JAMA (1996) 4.80
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (1998) 4.07
Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA (1997) 4.00
Prevalence of Alzheimer's disease and other dementias in rural India: the Indo-US study. Neurology (1998) 3.82
Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol (2001) 3.80
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 3.77
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 3.74
Reduced plasma dehydroepiandrosterone concentrations in Alzheimer's disease. Lancet (1989) 3.69
The AD8: a brief informant interview to detect dementia. Neurology (2005) 3.65
Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology (2005) 3.55
Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study. Arch Gen Psychiatry (2001) 3.32
Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology (2001) 3.30
Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology (2007) 3.26
Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology (1996) 3.23
Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage (2005) 3.21
A longitudinal study of drivers with Alzheimer disease. Neurology (2008) 3.17
Diagnosis and treatment of depression in late life. Consensus statement update. JAMA (1997) 3.14
Functional brain imaging of young, nondemented, and demented older adults. J Cogn Neurosci (2000) 3.12
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry (2001) 3.09
A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology (2000) 2.99
Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology (2001) 2.99
The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging (1992) 2.97
Protection against Alzheimer's disease with apoE epsilon 2. Lancet (1994) 2.96
Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem (1986) 2.95
Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades. Arch Gen Psychiatry (1999) 2.89
Mild cognitive impairment in the elderly: predictors of dementia. Neurology (1991) 2.83
Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79
American Academy of Neurology position statement on physician reporting of medical conditions that may affect driving competence. Neurology (2007) 2.79
Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. Neurology (2000) 2.79
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology (2009) 2.76
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry (2001) 2.74
Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology (1998) 2.70
Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging (1997) 2.68
Caregiver well-being: a multidimensional examination of family caregivers of demented adults. Gerontologist (1986) 2.68
Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry (1987) 2.65
Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology (2000) 2.64
Treatment of traumatic brain injury with moderate hypothermia. N Engl J Med (1997) 2.62
Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol (2001) 2.51
Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull (1988) 2.50
Reliability of the Washington University Clinical Dementia Rating. Arch Neurol (1988) 2.48
The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis (2005) 2.47
Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ (2006) 2.47
The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol (1993) 2.44
A chart review study of late-onset and early-onset schizophrenia. Am J Psychiatry (1989) 2.44
Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am J Psychiatry (1990) 2.41
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology (2001) 2.38
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA (2001) 2.36
Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type. Neurology (2000) 2.31
A comprehensive support program: effect on depression in spouse-caregivers of AD patients. Gerontologist (1995) 2.26
A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol (1998) 2.22
Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology (2004) 2.20
Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry (2000) 2.19
Global Deterioration Scale (GDS). Psychopharmacol Bull (1988) 2.14
Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging (1990) 2.14
Clinical-neuropathologic findings in multi-infarct dementia: a report of six autopsied cases. Neurology (1997) 2.13
Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology (2000) 2.10
The value of informant versus individual's complaints of memory impairment in early dementia. Neurology (2000) 2.10
Adrenal hemorrhage: a 25-year experience at the Mayo Clinic. Mayo Clin Proc (2001) 2.10
The temporal relationship between depressive symptoms and dementia: a community-based prospective study. Arch Gen Psychiatry (1999) 2.07
Vascular factors predict rate of progression in Alzheimer disease. Neurology (2007) 2.06
Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. J Clin Psychiatry (1990) 2.05
Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry (2000) 2.04
Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross-National Dementia Study. Arch Neurol (2000) 2.04
Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project. Neurology (2000) 2.03
An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease. Nat Genet (1999) 2.01
Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science (1986) 2.00
Depression without sadness: functional outcomes of nondysphoric depression in later life. J Am Geriatr Soc (1997) 2.00
Optimal use of blood tests for assessment of thyroid function. JAMA (1993) 2.00
Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol (1997) 1.98
Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol (1999) 1.93
The impact of dementia on the family. JAMA (1982) 1.92
Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology (2004) 1.92
Polymerase chain reaction for detection of Toxoplasma gondii. J Med Microbiol (1990) 1.89
Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc (1998) 1.88
Hereditary dysphasic disinhibition dementia: a frontotemporal dementia linked to 17q21-22. Neurology (1998) 1.85